Nabriva Therapeutics Appoints Dr. Christine Guico-Pabia, MD, as Chief Medical Officer
DUBLIN, Ireland and FORT WASHINGTON, Pa., October 01, 2021 (GLOBE NEWSWIRE) – Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced the appointment of Dr Christine Guico-Pabia, MD, MBA, MPH as Chief Medical Officer (CMO) effective October 1, 2021.
“We are very pleased that Christine is joining our management team. Christine brings a comprehensive profile to the role of CMO, with extensive experience in multiple therapeutic areas, from clinical development to post-market support of several commercial stage products during her remarkable career, ”said Ted Schroeder, CEO of Nabriva Therapeutics .
Dr Guico-Pabia brings over 30 years of global biopharmaceutical experience and extensive expertise at every stage of drug development, pharmacoeconomic research and outcomes, and medical affairs. She previously held leadership roles in small startups and large multinational corporations, including McKesson, Merck, Wyeth, Pfizer, and Metagenics.
Christine received her MD from Santo Tomas University School of Medicine in Manila, Philippines, her MBA from Temple University Fox School of Business in Philadelphia, PA, and her MPH from Bloomberg School of Public Health at Johns Hopkins University in Baltimore, Maryland.
“I am delighted to join the experienced management team of Nabriva Therapeutics during such an exciting time in the growth and evolution of the business. I look forward to working with the team to support the clinical benefits of our currently marketed products. In addition, I am excited to develop innovative therapies that address the urgent problem of antibiotic resistance and transform the lives of patients with infectious diseases, ”said Dr Guico-Pabia.
About Nabriva Therapeutics plc
Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics Receives U.S. Food and Drug Administration Approval For XENLETA® (injection of lfamulin, lfamulin tablets), the first systemic antibiotic based on pleuromutilin for community bacterial pneumonia (CAP). Nabriva Therapeutics is also developing CONTEPO ™ (fosfomycin) for injection, a first-class epoxy antibiotic with potential for complicated urinary tract infections (cUTI), including acute pyelonephritis. Nabriva has entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, NJ, USA to market, sell and distribute SIVEXTRO® (tedizolid phosphate) in the United States and some of its territories.
All statements in this press release regarding the future expectations, plans and prospects of Nabriva Therapeutics, including, but not limited to, statements about the potential benefits to Nabriva Therapeutics in connection with its promotion agreement sales and distribution with subsidiaries of Merck & Co. Inc., Kenilworth, NJ, USA the potential patient benefits of SIVEXTRO and XENLETA, the market opportunity for SIVEXTRO and XENLETA, the availability of SIVEXTRO by the intermediary of the main American specialized wholesalers, the impact on the declared revenues of Nabriva Therapeutics from the anticipated sales of SIVEXTRO, the sufficiency of its cash resources and other statements containing the words “anticipate”, “believe”, “estimate”, ” expect ”,“ intend ”,“ may ”,“ plan ”,“ predict ”,“ plan ”,“ target ”,“ “likely”, “will”, “would”, “could”, “Dev rait ”,“ continue ”and similar expressions constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements due to a number of important factors, including: the ability of Nabriva Therapeutics to maintain the terms of the distribution agreement to distribute and promote SIVEXTRO exclusively, including its ability to maintain sufficient business infrastructure to promote and distribute SIVEXTRO, the extent of business disruptions resulting from the infection causing the outbreak of COVID-19 or similar public health crises, the ability to retain and hire key personnel, the availability of adequate additional funding on acceptable terms or not at all and any other material factors as stated in the annual and quarterly reports of Nabriva Therapeutics and in other documents filed with the SEC. In addition, the forward-looking statements included in this press release represent the views of Nabriva Therapeutics as of the date of this press release. Nabriva Therapeutics anticipates that subsequent events and developments could change its point of view. However, although Nabriva Therapeutics may choose to update these forward-looking statements at some time in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be taken as representing the views of Nabriva Therapeutics as of a date subsequent to the date of this press release.
Nabriva Therapeutics plc
For the media